1. Biryukova E.V., Markin N.V., Garbuzova M.A. Efficient and flexible bariatrics pharmacotherapy nowadays is the key to successful diabetes prevention in future. Sakharnyy diabet. 2007; (4): 23—8. (in Russian)
2. Kotlovskiy M.Yu., Kotlovskaya O.S., Osedko O.Ya. et al. The impact of the first type receptor of angiotensinogen II polymorphism on the body function systems in patients with hypertension and chronic form of ischemic heart disease. Mezhdunarodnyy zhurnal prikladnykh i fundamental'nykh issledovaniy. 2011; (12): 56—8. (in Russian)
3. Tseluyko V.I., Brigvadze T.Z., Mishuk N.E. et al. Polymorphism of angiotensin II receptor gene of the first type and its influence on the olmesartan therapy effect in patients with GB. Ukrainskiy Khar'kovskiy zhurnal. 2013; (4): 21—7. (in Russian)
4. Kulikova M.V., Astseulova T.V. The renin-angiotensin system components and role of systemic inflammation in patients with hypertension associated with type 2 diabetes. Nauchnye vedomosti. Seriya: Meditsina. Farmakologiya. 2014; 18 (189). — Vypusk 27: 50—2. (in Russian)
5. Chistyakov D.A., Kobalava Zh.D., Tereshchenko S.N., Moiseev S.V., Nosikov V.V. Polymorphism of angiotensinogen gene vascular receptor II and cardiovascular diseases. Ter. arkh. 2000; (4): 27—30. (in Russian)